| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6465 | 2015 |
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer T Powles, JP Eder, GD Fine, FS Braiteh, Y Loriot, C Cruz, J Bellmunt, ... Nature 515 (7528), 558-562, 2014 | 2607 | 2014 |
| Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre … TY Seiwert, B Burtness, R Mehra, J Weiss, R Berger, JP Eder, K Heath, ... The lancet oncology 17 (7), 956-965, 2016 | 1691 | 2016 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1320 | 2016 |
| Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial K Muro, HC Chung, V Shankaran, R Geva, D Catenacci, S Gupta, JP Eder, ... The lancet oncology 17 (6), 717-726, 2016 | 1141 | 2016 |
| Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ... Journal of Clinical Oncology 37 (28), 2518, 2019 | 1055 | 2019 |
| Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE … LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ... Journal of Clinical Oncology 34 (32), 3838, 2016 | 860 | 2016 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 707 | 2019 |
| Novel therapeutic inhibitors of the c-Met signaling pathway in cancer JP Eder, GF Vande Woude, SA Boerner, PM LoRusso Clinical Cancer Research 15 (7), 2207-2214, 2009 | 635 | 2009 |
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors D Strumberg, JW Clark, A Awada, MJ Moore, H Richly, A Hendlisz, ... The oncologist 12 (4), 426-437, 2007 | 485 | 2007 |
| A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard … K Antman, L Ayash, A Elias, C Wheeler, M Hunt, JP Eder, BA Teicher, ... Journal of clinical oncology 10 (1), 102-110, 1992 | 433 | 1992 |
| Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors JW Clark, JP Eder, D Ryan, C Lathia, HJ Lenz Clinical Cancer Research 11 (15), 5472-5480, 2005 | 425 | 2005 |
| Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ... British journal of cancer 119 (2), 153-159, 2018 | 405 | 2018 |
| A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors KK Wong, PM Fracasso, RM Bukowski, TJ Lynch, PN Munster, GI Shapiro, ... Clinical cancer research 15 (7), 2552-2558, 2009 | 385 | 2009 |
| Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily JP Eder Jr, JG Supko, JW Clark, TA Puchalski, R Garcia-Carbonero, ... Journal of Clinical Oncology 20 (18), 3772-3784, 2002 | 374 | 2002 |
| A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer JP Eder, PW Kantoff, K Roper, GX Xu, GJ Bubley, J Boyden, L Gritz, ... Clinical Cancer Research 6 (5), 1632-1638, 2000 | 369 | 2000 |
| BET inhibitors: a novel epigenetic approach DB Doroshow, JP Eder, PM LoRusso Annals of Oncology 28 (8), 1776-1787, 2017 | 353 | 2017 |
| Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) LA Emens, FS Braiteh, P Cassier, JP Delord, JP Eder, M Fasso, Y Xiao, ... Cancer Research 75 (15_Supplement), 2859-2859, 2015 | 339* | 2015 |
| Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032 N Ready, AF Farago, F de Braud, A Atmaca, MD Hellmann, JG Schneider, ... Journal of Thoracic Oncology 14 (2), 237-244, 2019 | 312 | 2019 |
| A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas DS Hong, R Kurzrock, JG Supko, X He, A Naing, J Wheler, D Lawrence, ... Clinical cancer research 18 (12), 3396-3406, 2012 | 247 | 2012 |
